# Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

> clinical trial · VERIFIED · 2026-07-22

Status: NOT_YET_RECRUITING · Sponsor: CSL Behring · Condition: Secondary Immune Deficiency

- Company: CSL Behring
- Sector: Secondary Immune Deficiency
- Primary source: https://clinicaltrials.gov/study/NCT07648264

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.